CD274 and non-small cell lung carcinoma: More recently, the phase III HARMONI-2 trial showed that first-line ivonescimab, a bispecific antibody targeting PD-1 and VEGF, significantly improved PFS over pembrolizumab (11.14 m vs. 5.82 m; HR 0.51; 95% CI0.38–0.69; p < 0.0001) in advanced NSCLC with a positive PD-L1 score.